Chiesi accelerates sustainable growth in 1st-half 2025

16 September 2025

Family-controlled Italian drugmaker Chiesi Group has announced financial results for the six months ended June 30, 2025.

Revenues totaled 1.86 billion euros ($2.18 billion), growing 201 million euros (+13.2% at CER) versus first-half 2024, and earnings before interest, taxes, depreciation and amortization (EBITDA) margin confirmed at around 30% reflecting strong sales growth and disciplined cost management.

Giuseppe Accogli, chief executive of Chiesi Group, commented on the results: “H1 2025 marks another step forward on our journey to create significant shared value, in line with the Group’s mission and vision. Robust top-line growth, disciplined cost control and continuous investment in innovation position us well for the challenges and opportunities ahead.”

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK